The risk of bleeding for antiplatelet agents in Haemodialysis patients: A Meta-analysis

1Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

Abstract

Background: The safety of antiplatelet therapy in haemodialysis (HD) patients remains controversial. we conducted the first meta-analysis to evaluate the bleeding risk with antiplatelet agents in these populations. Methods: The relevant literature was searched using the following electronic databases without any language restrictions: The Cochrane Library, EMBASE, Global Health, MEDLINE, PubMed, and the Chinese Biomedical Database. Results: Seven randomized controlled trials (RCTs) and 2 prospective cohort studies, consisting of 1131 patients, were identified for detailed evaluation. The meta-analysis suggested that the use of double antiplatelet agents increased the risk of bleeding in HD patients [odds ratio (OR) = 2.78; 95% confidence interval (CI) 1.63 to 4.76; I 2 = 0], and antiplatelet agents increased the risk of bleeding in 7 RCTs [odds ratio (RR) = 1.40, 95% CI 1.08 to 1.79; I 2 = 23%,]; however, the use of a single antiplatelet agent was not found to significantly increase the risk of bleeding (RR = 0.88; 95% CI 0.51 to 1.50; I 2 = 0). Conclusion: The results suggested that the use of double antiplatelet agents increased the risk of bleeding in HD patients.

Cite

CITATION STYLE

APA

Wang, Q., Xie, X., & Xu, G. (2020). The risk of bleeding for antiplatelet agents in Haemodialysis patients: A Meta-analysis. BMC Nephrology, 21(1). https://doi.org/10.1186/s12882-020-01757-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free